|
|
|
Sponsored by:
|
|
Other qualified titles include: Chairman, President, Chief
Operating Officer, Executive Vice Presidents and Department Heads
Or please submit a Request for Summit Invitation |
|
- M O N D A Y , J A N U A R Y 2 6 , 2 0 0 4
- |
| |
| 2:45 |
FDA Update in Election Year 2004
- Major potential changes in regulatory compliance
- Regulations in manufacturing, clinical and marketing and
compliance
- Medicare and Medicaid – Public purchaser demands and working
with State and Federal contracts
Mark McClellan, MD, Commissioner, Food and Drug Administration |
| 4:15 |
Strategies to Increase Output Productivity in Research
Labs
- Reasons for decrease in productivity
- Organizational structural approaches
- Chemical biology – A knowledge platform
- Pre-competitive consortia
Frank Douglas, Executive Vice President for Drug Innovation and
Approval, and Chief Scientific Officer, Aventis Pharmaceuticals |
| 5:00 |
New Business Strategies and Models to Compete in an Era
of Consumerism in Healthcare
- Analysis of changing market conditions for utilization and
access to drugs
- Building the case for the value of pharmaceuticals and
determining whether insurers will pay
- How consumerism will impact Medicare and Medicaid
populations
Moderator: Scott Hensley, Staff Reporter, The Wall Street
Journal
Henry A. McKinnell, Jr., Ph.D., Chairman and CEO, Pfizer Inc |
| |
|
- T U E S D A Y , J A N U A R Y 2 7 ,
2 0 0 4 - |
| 9:15 |
Updates on FDA Efforts to Improve the Efficiency and
Effectiveness of Drug Development
- New FDA initiatives to improve drug development and
agency review processes
- Pharmacogenomics — Guidance addressing key regulatory questions
- Interagency Oncology Task Force activities to facilitate cancer
drug development
Theresa M. Mullin, PhD, Assistant Commissioner, Food and Drug
Administration
John Jenkins, MD, Director, Office of New Drugs, Food and Drug
Administration
|
| 10:00 |
Evolving Customer Relationships – Partnership Strategies
with PBMs
- Maintaining high consumer satisfaction while keeping
prescription drug costs down
- Engaging consumers in their prescription benefit through
more choice and incentives
- Meeting the challenge of making new, high cost biotech
drugs affordable
- Making the use of prescription drugs safer
Sarah S. Harrison, Vice President, Customer Strategy Integration,
AstraZeneca Pharmaceuticals; 2002 Healthcare Businesswoman of the Year |
| 11:15 |
Challenges and Opportunities in R&D and Marketing of
Targeted Therapies
- Examples and discussion of targeted therapies
- Difficulties of recruiting patients for trials
- Issues of providing access to patients in the early
stages and the often unrecognized need of marketing these
kinds of therapies
David Epstein, President, Novartis Oncology |
| |
|
|
